Sorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R … – StreetInsider.com
EconoTimesSorrento Therapeutics (SRNE), Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With R/R …StreetInsider.comSorrento Therapeutics, Inc. (NASDAQ: SRNE) and Celularity Inc announced today that the companies have started sc… Continue reading
